<DOC>
	<DOC>NCT01234129</DOC>
	<brief_summary>Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.</brief_summary>
	<brief_title>Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma</brief_title>
	<detailed_description>Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma whose are treated with cytoreductive therapy and stem cell transplant.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage III ( DurieSalmon) No severe comorbidities Pregnancy HIV + Refuse treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>